Silverstein FNDN

The Silverstein Foundation: Accelerating research in Parkinson's with GBA

[Silverstein FNDN @silversteinFNDN]

Thank you for having us @ZivGanOr! Excited to begin.

[Ziv Gan-Or @ZivGanOr]

Now at the #GBA1Meeting pre-meeting of the @silversteinFNDN, which sponsors 12 fellows around the world who study GBA1.

[Silverstein FNDN @silversteinFNDN]

The first in-person meeting of The Silverstein Foundation Fellows. All gathered at the GBA1 meeting at @TheNeuro_MNI. Excited to hear updates from all of our fellows. #cureGBAPD

[The Science of Parkinson's @ScienceofPD]

The Silverstein Foundation @silversteinFNDN launches a program of 2-year, post-doctoral fellowships to fund 11 scientists working on novel research for #Parkinsons in GBA mutation carriers
https://t.co/W2dqLb0N9u

[Ziv Gan-Or @ZivGanOr]

One of the best ways to invest in research is to invest in people. I'm very grateful that the @silversteinFNDN have selected us as one of the centers to receive funding for a 2-years fellowship to study GBA1. Please contact me if you are interested.
https://t.co/PaJpy5EJTk

[Silverstein FNDN @silversteinFNDN]

We are excited to announce our new Post-Doctoral Fellowship Program today. #cureGBAPD https://t.co/FJzAbggTWS

[The Science of Parkinson's @ScienceofPD]

New clinical study registered: @ScottNYSCF & colleagues at the @nyscf & @silversteinFNDN are seeking skin biopsies &/or blood cells from people with GBA-associated #Parkinsons for drug discovery projects
https://t.co/VVb319MPDm

[Silverstein FNDN @silversteinFNDN]

Proud of this announcement and our partnership with @VanquaBio

[Vanqua Bio @VanquaBio]

Vanqua Bio is pleased to announce we have closed an $85 million Series B financing round, led by Omega Funds. We’re excited to help usher in a new era of hope for patients living with neurodegenerative disorders.

Learn more: https://t.co/Wo4bxriRu9 #Biopharma

[Silverstein FNDN @silversteinFNDN]

"Vanqua Bio is helping usher in a new era of hope for people living with neurodegenerative disorders.” - Jim Sullivan, PhD, Co-founder and CEO of Vanqua Bio

[BiotechTechNow @MedTechNow_]

More #Funding & #Grants

@dnanudge completion of $60M #SeriesA #Investment Led by #VenturaCapital

@OxBioDynamics awarded #FNIH #grant for applications for to apply #EpiSwitch® #ImmuneHealth test
#Cancer #Therapies

@silversteinFNDN funding for #AcureXTherapeutics
#Parkinsons

[Silverstein FNDN @silversteinFNDN]

We are proud to announce another transformative grant in Parkinson’s with GBA https://t.co/AxtMbRbVvV

[Silverstein FNDN @silversteinFNDN]

Exciting News from The Silverstein Foundation https://t.co/m1dgNdvh1g

[Silverstein FNDN @silversteinFNDN]

Today is #GivingTuesday a global generosity movement for giving to the causes you care most about. Help us beat Parkinson's #Parkinsons #cureGBA https://t.co/O5LBQxjdjE

[Silverstein FNDN @silversteinFNDN]

@MichaelJFoxOrg Co-founder @natsilverstein was honored to attend the #foxgala Saturday night,celebrating the amazing work of @MichaelJFoxOrg. It was a special night (with @realmikefox jamming on guitar!) @silversteinFNDN is proud to partner with @MichaelJFoxOrg in our tireless pursuit of a cure.

[Benjamin Stecher @Neuronologist1]

@immunoresolvent Just a few of the programs that will forever change PD (& more) in the decade to come...

@silversteinFNDN
@CureParkinsonsT's LCT
@TheNeuro_MNI's OS
@C_R_A_N_I_A
@thesgconline
ASAP (needs @ @ELeap29 ;)
CCBP (ditto)
@LashuelLab
@cziscience
@AllenInstitute
@predictPD
@pdgenetics

[Silverstein FNDN @silversteinFNDN]

The @MichaelJFoxOrg featured #PrevailTherapeutics in a blog post announcing recruitment for the PROPEL trial, a #genetherapy clinical trial for PD patients with a GBA mutation. Read the blog here: https://t.co/yo0E88PxCW Learn more about the trial here: https://t.co/pTTUz1GyIl

[Silverstein FNDN @silversteinFNDN]

Last week the @silversteinFNDN held it’s 3rd annual Scientific Advisory Board meeting, focusing on 8 different therapeutic approaches that we have funded. In all, we have made 32 grants since our launch in 2017. We will put our 3rd drug into human trials in mid-Nov. #cureGBA

[The Science of Parkinson's @ScienceofPD]

Interesting new clinical trial registered by @PPRI__ with support from @MichaelJFoxOrg & @silversteinFNDN to analyze the molecular & clinical mechanisms of the relationship between the GBA mutations & #Parkinsons
https://t.co/GtznZibXJp

[The Science of Parkinson's @ScienceofPD]

This is a @silversteinFNDN-supported project, which we have previously discussed on the SoPD website:
https://t.co/kaCyjgaSHl

[The Science of Parkinson's @ScienceofPD]

New company Surmount Bio has been set up to explore & develop S-181 further. Backed by @silversteinFNDN-associated @OrbiMed - Wow, a lot happening in the GBA-#Parkinsons world! Prevail, Surmount,... what next?

[The Science of Parkinson's @ScienceofPD]

@BrundinPatrik @Neuronologist1 We are making some bold assumptions with the current stock of GBA-#Parkinsons trials. A lot of questions regarding our understanding of that 'sub-type' will be answered by those trials. But while those trials play out (with significant support from groups like @silversteinFNDN..